Intraperitoneal biotherapy of malignant peritoneal effusions in ovarian cancer patients
https://doi.org/10.17650/1994-4098-2012-0-3-4-169-172
Abstract
Malignant peritoneal effusions often arise in patients with of ovarian cancer. They are dangerous complication of cancer. Intraperitoneal chemotherapy isn’t always effective and causes side effects. Intraperitoneal interleukin-2 (IL-2) and IL-2 / lymphokine activated killers (LAK) biotherapy is characterised of high efficacy in ovarian cancer patients with malignant peritoneal effusions. The objective effect was 82,6 % аnd 72,0 % accordingly. These results suggest that intraperitoneal biotherapy allows to expand possibilities of malignant peritoneal effusions treat- ment in ovarian cancer patients.
About the Authors
К. S. Titov
N.N. Blokhin Russian Cancer Research Center RAMS, Moscow
Russian Federation
Russian Federation
A. N. Gritsai
N.N. Blokhin Russian Cancer Research Center RAMS, Moscow
Russian Federation
Russian Federation
L. V. Demidov
N.N. Blokhin Russian Cancer Research Center RAMS, Moscow
Russian Federation
Russian Federation
L. M. Rodionova
N.N. Blokhin Russian Cancer Research Center RAMS, Moscow
Russian Federation
Russian Federation
M. V. Kiselevsky
N.N. Blokhin Russian Cancer Research Center RAMS, Moscow
Russian Federation
Russian Federation
M. V. Mosina
N.N. Blokhin Russian Cancer Research Center RAMS, Moscow
Russian Federation
Russian Federation
References
1. Гарин А.М., Базин И.С. Десять наиболее распространенных злокачественных опухолей. М., 2006. С. 205.
2. Давыдов М.И., Летягин В.П., Кузнецов В.В. Рак яичников. В кн.: Опухоли женской репродуктивной системы. М.: Радуга, 2007. С. 164−176; 273−82.
3. Киселевский М.В., Блюменберг А.Г. Адоптивная иммунотерапия рака яичников. Сборник статей, приуроченный к Европейской школе по онкологии, 2001.
4. Markman M. Intraperitoneal chemotherapy of ovarian cancer. Semin Oncol 1998;25:356−60.
5. Feedman R.S., Kudelka A.P., Kavanagh J.J. Clinical and Biological Effects of Intraperitoneal Injections of Recombinant Interferon- and Recombinant Interleukin-2 with or without Tumor-infiltrating Lympho- cytes in Patients with Ovarian or Peritoneal Carcinoma. Clin Cancer Res 2000;6:225−6.
6. Nagamine I., Yamaguchi Y., Ohara M.et al. Induction of gamma delta T-cells using zoledronate plus interleukin-2 in patients with metastatic cancer. Hiroshima J Med Sci 2009; 58:37−44.
7. Pujade-Lauraine E., Guastella J.P., Colombo N. et al. Intraperitoneal ecombinant interferon-γ in ovarian cancer patients with residual disease at second-look laparotomy. J Clin Oncol 1996;14:343−50.
8. Hua Z., Lit J. Clinical study on immunotherapy of ovarian canser with tumor infiltrating lumphocytes. Chung Yua Fu 1996; 13:555−7.
Review
For citations:
Titov К.S., Gritsai A.N., Demidov L.V., Rodionova L.M., Kiselevsky M.V., Mosina M.V. Intraperitoneal biotherapy of malignant peritoneal effusions in ovarian cancer patients. Tumors of female reproductive system. 2012;(3-4):169-172. (In Russ.) https://doi.org/10.17650/1994-4098-2012-0-3-4-169-172
Views:
529
Email this article 